Results: Bladder Cancer

Results from Abstracts

Pick one of the followings

*Some genes may be words of complete meaning. In any case, if present, they are relevant key words.

Legend:

***	p-value <= 0.001
**	p-value <= 0.01
*	p-value <= 0.05
n.s.	not significant

Top Ranked Genes, Molecules or Short Names*

Hr ***
Cs **
Ubc **
Fgfr3 *
Cdh3 *
Gpr126 *
Ccr4 *
Fam107a *
Oip5 *
Iqgap3 *
Hoxb5 *
Ogg1 *
Elf3 *
Stil *
Cck *
Vamp2 *
Mapk3 *
Hmga1 *
Impact *
Cd24 *
Tagln2 *
Bmp4 *
Ep300 *
Sfn *
Dancr *
Lag3 *
Thbs2 *
Fasn *
Hcg22 n.s.
Krt14 n.s.
Tigit n.s.
Tln1 n.s.
Nin n.s.
Sgk1 n.s.
Col3a1 n.s.
Arid1a n.s.
Ccnb1 n.s.
Col6a3 n.s.
Ccnd2 n.s.
Usp8 n.s.
Eif4e n.s.
Psca n.s.
Nodal n.s.
Gstm1 n.s.
Pdgfb n.s.
Top2a n.s.
Ptgs2 n.s.
Nqo1 n.s.
Stat3 n.s.
Esr1 n.s.
Cd80 n.s.
Rela n.s.
Foxm1 n.s.
Atg7 n.s.
Met n.s.
Cd44 n.s.
Vip n.s.
Col6a1 n.s.
Ugt1a1 n.s.
Acta2 n.s.
Gstt1 n.s.
Ccl2 n.s.
Shh n.s.
Sry n.s.
Ctla4 n.s.
Mal n.s.
Kdm6a n.s.
Sp1 n.s.
Cit n.s.
Ar n.s.
Erbb2 n.s.
Aes n.s.
Cdk4 n.s.
Pten n.s.
Itga3 n.s.
Col1a1 n.s.
Dhcr24 n.s.
Greb1 n.s.
Nuak2 n.s.
Tyro3 n.s.
Pcdh17 n.s.
Hoxa9 n.s.
Cebpa n.s.
Pou4f2 n.s.
Onecut2 n.s.
Fancg n.s.
Fancl n.s.
Otc n.s.
Rhob n.s.
Ahnak2 n.s.
Eefsec n.s.
Sepsecs n.s.
Aqp3 n.s.
Secisbp2 n.s.
Mtf1 n.s.
Pstk n.s.
Cd3d n.s.
Tsga10 n.s.
Ciz1 n.s.
Stk32c n.s.

Top Ranked Key Phrases

Bacillus calmette guÉrin bcg ***
Long non coding rnas lncrnas ***
Non muscle invasive bladder cancer ***
Robot assisted radical cystectomy rarc ***
Nonmuscle invasive bladder cancer nmibc ***
Muscle invasive bladder cancer mibc ***
Long noncoding rnas lncrnas ***
Upper tract urothelial carcinoma ***
Muscle invasive bladder cancer ***
Epithelial mesenchymal transition emt ***
Bladder cancer cell lines ***
Quantitative real time pcr ***
Human bladder cancer cells ***
Recurrence free survival rfs ***
High grade bladder cancer ***
Urothelial bladder cancer ubc ***
Cancer specific survival css ***
Non muscle invasive ***
Progression free survival pfs ***
Patients undergoing radical cystectomy ***
Cancer genome atlas ***
Kaplan meier curves **
Muscle invasive disease **
Luciferase reporter assay **
Optical coherence tomography **
Kaplan meier method **
Bc cell lines **
Cell cycle arrest **
Invasive bladder cancer **
Renal cell carcinoma **
Urothelial carcinoma uc **
Log rank test **
Immune checkpoint inhibitors **
Metastatic urothelial carcinoma **
Pd l1 expression **
Circular rnas circrnas **
Lymph node involvement **
Human bladder cancer **
Disease free survival **
Lymph node metastasis **
Urothelial bladder cancer **
Cancer specific survival **
Adjacent normal tissues **
Wound healing assay **
Urinary bladder cancer **
Bladder cancer bc **
Recurrence free survival **
Radical cystectomy rc **
Long term follow **
Metastatic bladder cancer **
Primary bladder cancer **
Bladder cancer cells *
Bladder cancer tissues *
Advanced bladder cancer *
Cancer specific mortality *
Bladder cancer therapy *
Progression free survival *
Underwent radical cystectomy *
Real time pcr *
Western blot analysis *
Cell cycle progression *
Cisplatin based chemotherapy *
Overall survival os *
Bladder cancer risk *
Independent prognostic factor *
Bladder cancer bca *
Health related quality *
Bladder tumor turbt *
Molecular mechanisms underlying *
Novel therapeutic target *
Bladder cancer treatment *
Low grade tumors *
Bladder cancer progression *
Present study was *
High recurrence rate *
Neoadjuvant chemotherapy nac *
Potential therapeutic targets *
Muscle invasive *
Bladder cancer diagnosis *
High risk nmibc *
95% confidence intervals cis *
Bladder cancer patients *
Potential therapeutic target *
Preferred reporting items *
High risk patients *
Low certainty evidence n.s.
Cisplatin ineligible patients n.s.
Present study demonstrated n.s.
Cell lines n.s.
Pd l1 n.s.
95% confidence interval ci 1 n.s.
95% confidence interval ci n.s.
Urinary tract n.s.
Urothelial carcinoma n.s.
Cell cycle n.s.
Ileal conduit n.s.

Top Ranked Mesh Terms

Prognosis ***
Humans ***
Aged 80 and over ***
Micrornas ***
Male ***
Neoplasm invasiveness ***
Retrospective studies ***
Apoptosis ***
Urinary bladder neoplasms ***
Biomarkers tumor ***
Carcinoma transitional cell ***
Methods ***
Disease progression ***
Cell proliferation ***
Cystectomy ***
Treatment outcome ***
Aged ***
Neoplasm recurrence local ***
Middle aged ***
Drug therapy ***
Adult ***
Female ***
Cell line tumor ***
Pathology ***
Urinary bladder ***
Gene expression regulation neoplastic ***
Genetics ***
Administration intravesical ***
Neoplasm staging ***
Mortality ***
Cell movement ***
Kaplan-meier estimate ***
Diagnosis ***
Risk factors **
Antineoplastic agents **
Postoperative complications **
Neoplasm grading **
Epidemiology **
Rna long noncoding **
Mice nude **
Signal transduction **
Disease-free survival **
Bcg vaccine **
Metabolism **
Follow-up studies **
Urine **
Cisplatin **
Survival analysis **
Prospective studies **
Xenograft model antitumor assays **
Immunohistochemistry **
Immunotherapy **
Survival rate **
Antineoplastic combined chemotherapy protocols **
Proportional hazards models **
Down-regulation *
Urologic neoplasms *
Risk assessment *
Cystoscopy *
Cohort studies *
Drug resistance neoplasm *
Pharmacology *
Incidence *
Cell cycle *
Adjuvants immunologic *
Urothelium *
Mitomycin *
Prostatic neoplasms *
Genetic predisposition to disease *
Sarcopenia *
Cytochromes c *
Propensity score *
Antibiotic prophylaxis *
Cyclin b1 *
Histone deacetylase inhibitors *
Autophagy-related protein 7 *
Morbidity *
Laparoscopy *
Infusions intra-arterial *
Molecular imaging *
Injections intradermal *
Methotrexate *
Transfection *
Receptors somatomedin *
Angiogenesis inhibitors *
Carcinoma papillary *
Referral and consultation *
Transforming growth factor beta1 *
Multimodal imaging *
United states food and drug administration *
T-lymphocytes cytotoxic *
Neoplasm metastasis *
Mice inbred balb c *
Graphite *
Arsenic *
Ppar gamma *
Ribonucleoproteins *
Neoplastic stem cells *
Standard of care *
Intestinal obstruction *

Top Ranked Mesh Terms (Symptoms)

Neoplasm invasiveness ***
Neoplasm recurrence local ***
Disease progression ***
Postoperative complications **
Genetic predisposition to disease *
Sarcopenia *
Neoplasm metastasis *
Urinary bladder overactive *
Asymptomatic diseases *
Urinary incontinence *
Neoplasm residual *
Carcinogenesis *
Cachexia *
Hematuria *
Lymphatic metastasis *
Neovascularization pathologic *
Blood loss surgical n.s.
Lower urinary tract symptoms n.s.
Cell transformation neoplastic n.s.
Micronuclei chromosome-defective n.s.
Recurrence n.s.
Microsatellite instability n.s.
Cancer pain n.s.
Adenocarcinoma in situ n.s.
Urinary bladder neurogenic n.s.
Pelvic organ prolapse n.s.
Chronic pain n.s.
Intraoperative complications n.s.
Genomic instability n.s.
Emphysema n.s.
Pain n.s.
Margins of excision n.s.
Seizures n.s.
Disease susceptibility n.s.
Hypoxia n.s.
Fever n.s.
Overweight n.s.
Weight loss n.s.
Cellulitis n.s.
Prosthesis-related infections n.s.
Inflammation n.s.
Hemolysis n.s.
Obesity n.s.

Results for: Bladder Cancer

Results from Abstracts

KEGG Pathways

Gene Ontology Biological Processes